Aussie cost watchdogs slam cancer pricing in leaked report; Novartis lays off 89 at NY plant;

@FiercePharma: Sanofi's Shantha ready to supply 37 million doses of long-delayed pentavalent. FierceVaccines story | Follow @FiercePharma

@EricPFierce: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce

@CarlyHFierce: Don't forget that there are FOUR regions to vote in today - let's show the oncology drugs some love, shall we? More on FierceMadness | Follow @CarlyHFierce

> In a leaked report to Australia's Senate, cost-effectiveness watchdogs slammed big drugmakers for high cancer drug prices, particularly those with smaller survival benefits. Report

> As part of an ongoing cost-cutting drive, Novartis ($NVS) is laying off 89 workers in Suffern, NY, where a plant is slated for closure. Report

> Investment in the Indonesian drug industry isn't growing much, despite a government program for universal insurance coverage. Report

> Antipsychotic drugs may be more dangerous to elderly patients than previously thought, according to a new study. Report

Medical Device News

@FierceMedDev: ICYMI: Vivo Capital doubles down to close $750M US-China healthcare fund. Story | Follow @FierceMedDev

@VarunSaxena2: Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Story | Follow @VarunSaxena2

@EmilyWFierce: Changes in public's perceptions of risk contributes to spread of infectious diseases, says NIAID director. More from The Atlantic | Follow @EmilyWFierce

> Boston Scientific subsidiary hit with $50M gender discrimination suit. Report

> Canon BioMedical makes first move with rapid DNA, drug metabolism diagnostic startup. Story

> Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Article

Biotech News

@FierceBiotech: J&J stays mum about cash, but biotech buyout is a landmark win for Index fund. Story | Follow @FierceBiotech

@JohnCFierce: Crohn's expert flags blockbuster potential--and frets--of Celgene's mongersen. News | Follow @JohnCFierce

@DamianFierce: Today begins the round of 64 in FierceMadness, a pointless & absurd tournament of drug names. More | Follow @DamianFierce

> Lilly inks a $690M deal to get its hands on an autoimmune drug. Article

> Genmab buys iDD antibody assets, drops ADC co-development rights. Story

> Google's mystery biotech Calico partners with the Broad on aging-related drugs. News

CRO News

> Quintiles taps Google partner Tute Genomics for R&D. Item

> Trial tech outfit Clinical Ink merges with app upstart. News

> Evotec pairs up with Second Genome to gut out some R&D. More

> Catalent shakes up its business with an eye on product launches. Story

> WuXi dives into the CAR-T fray with new plant plans. Article

Vaccines News

> Cancer vaccine maker Aduro files for $86M IPO. Item

> Allergy Therapeutics scores $30M to finish grass allergy vaccine. More

> England to provide GSK MenW vaccine to 3 million teens. News

> GSK to test Ebola jab with booster from Emergent BioSolutions. Report

> More vaccines deals for Pfizer? It wouldn't say no, exec says. Story

Pharma Manufacturing News

> Puerto Rico manufacturing base to grow with AbbVie expansion. More

> Kite Pharma adds manufacturing assets with T-Cell Factory acquisition. Item

> India's Micro Labs recalls drugs made at banned plant. Report

> Wockhardt says FDA impressed by the strides it made at a banned plant. Article

> Lawsuit would force FDA to ban or label wheat gluten as ingredient. Story

Pharma Asia News

> U.S.-based lawsuits pile up for Japan's Olympus in superbug case. Item

> Indonesia drug industry investment lags despite universal insurance program. Article

> Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights. Story

> U.S. FDA softens approach in meetings with Indian regulators. Report

> India's Wockhardt, Granules, suggest recent FDA inspections went well. More

And Finally... Coke ($KO) and Pepsi ($PEP) are searching for a new generation of sweeteners for diet soda. Report